These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 24412186)

  • 1. CMR-based differentiation of AL and ATTR cardiac amyloidosis.
    Dungu JN; Valencia O; Pinney JH; Gibbs SD; Rowczenio D; Gilbertson JA; Lachmann HJ; Wechalekar A; Gillmore JD; Whelan CJ; Hawkins PN; Anderson LJ
    JACC Cardiovasc Imaging; 2014 Feb; 7(2):133-42. PubMed ID: 24412186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Fontana M; Pica S; Reant P; Abdel-Gadir A; Treibel TA; Banypersad SM; Maestrini V; Barcella W; Rosmini S; Bulluck H; Sayed RH; Patel K; Mamhood S; Bucciarelli-Ducci C; Whelan CJ; Herrey AS; Lachmann HJ; Wechalekar AD; Manisty CH; Schelbert EB; Kellman P; Gillmore JD; Hawkins PN; Moon JC
    Circulation; 2015 Oct; 132(16):1570-9. PubMed ID: 26362631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study.
    Deux JF; Damy T; Rahmouni A; Mayer J; Planté-Bordeneuve V
    Amyloid; 2014 Dec; 21(4):246-55. PubMed ID: 25211144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains.
    Slivnick JA; Alvi N; Singulane CC; Scheetz S; Goyal A; Patel H; Sarswat N; Addetia K; Fernandes F; Vieira MLC; Cafezeiro CRF; Carvalhal SF; Simonetti OP; Singh J; Lang RM; Zareba KM; Patel AR
    Eur Heart J Cardiovasc Imaging; 2023 May; 24(6):829-837. PubMed ID: 36624559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.
    Syed IS; Glockner JF; Feng D; Araoz PA; Martinez MW; Edwards WD; Gertz MA; Dispenzieri A; Oh JK; Bellavia D; Tajik AJ; Grogan M
    JACC Cardiovasc Imaging; 2010 Feb; 3(2):155-64. PubMed ID: 20159642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis.
    Fikrle M; Palecek T; Masek M; Kuchynka P; Straub J; Spicka I; Rysava R; Linhart A
    Clin Physiol Funct Imaging; 2016 May; 36(3):218-24. PubMed ID: 25393773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.
    Kravchenko D; Isaak A; Zimmer S; Öztürk C; Mesropyan N; Bischoff LM; Voigt M; Ginzburg D; Attenberger U; Pieper CC; Kuetting D; Luetkens JA
    Eur Heart J Cardiovasc Imaging; 2024 Jun; ():. PubMed ID: 38912832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
    Chatzantonis G; Bietenbeck M; Elsanhoury A; Tschöpe C; Pieske B; Tauscher G; Vietheer J; Shomanova Z; Mahrholdt H; Rolf A; Kelle S; Yilmaz A
    Clin Res Cardiol; 2021 Apr; 110(4):555-568. PubMed ID: 33170349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
    Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
    JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].
    Cui Q; Yu J; Shen W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1538-1541. PubMed ID: 32029045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of cardiac magnetic resonance imaging for the diagnosis of cardiac amyloidosis].
    Zhu KB; Cheng ZW; Tian Z; Zhao DC; Liu YT; Lin X; Chen TB; Xie HZ; Zeng Y; Fang LG; Jiang XC; Cui QC; Fang Q
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):915-9. PubMed ID: 22321275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular magnetic resonance in cardiac amyloidosis.
    Maceira AM; Joshi J; Prasad SK; Moon JC; Perugini E; Harding I; Sheppard MN; Poole-Wilson PA; Hawkins PN; Pennell DJ
    Circulation; 2005 Jan; 111(2):186-93. PubMed ID: 15630027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
    Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
    J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.
    Raina S; Lensing SY; Nairooz RS; Pothineni NV; Hakeem A; Bhatti S; Pandey T
    JACC Cardiovasc Imaging; 2016 Nov; 9(11):1267-1277. PubMed ID: 27568115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
    Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.